Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Multi-disease testing sits at the center of this dementia and brain health question.
Multi-disease testing could transform brain health screening by detecting the earliest signs of Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, and other neurological conditions through a single blood test—before symptoms appear. Instead of requiring expensive PET scans, spinal taps, or specialist evaluations, patients could receive comprehensive neurological screening through simple biomarker tests that measure abnormal proteins like plasma p-tau217 in their blood. This shift matters urgently: a new dementia case is diagnosed every 3 seconds globally, yet most people remain undiagnosed until irreversible brain damage has already occurred. The opportunity is substantial because many neurological diseases share overlapping biomarkers.
Researchers have discovered that blood biomarkers originally identified for Alzheimer’s disease can also detect Parkinson’s disease patients who have developed dementia, while tear fluid biomarkers show diagnostic implications across Alzheimer’s, Parkinson’s, and Multiple Sclerosis. When multiple diseases are screened simultaneously through a single panel, healthcare systems can identify which neurological pathway a person is on—and intervene earlier—without subjecting them to invasive procedures. This represents a fundamental change in how brain health screening could work. Rather than waiting for cognitive symptoms to become noticeable enough to warrant specialist referral, primary care offices could order a multi-disease biomarker panel as part of routine health maintenance, similar to how cholesterol and blood pressure screening work today.
Table of Contents
- What Are Multi-Disease Biomarkers and How Do They Work in Brain Health Screening?
- From Blood Tests to Early Detection: Replacing Invasive Diagnostic Methods
- Real-World Implementation: How Multi-Disease Testing Identifies Hidden Cognitive Decline
- The Cost and Accessibility Advantage of Screening Multiple Brain Diseases Simultaneously
- Limitations and Challenges in Multi-Disease Testing for Brain Health
- Emerging Technologies Beyond Blood Tests: Tear and Olfactory Biomarkers
- The Future of Brain Health Screening: Population-Wide Risk Assessment
- Conclusion
What Are Multi-Disease Biomarkers and How Do They Work in Brain Health Screening?
Multi-disease biomarkers are measurable biological signatures in blood, urine, or other body fluids that indicate the presence of neurological disease pathology—often years before a person notices memory loss, tremors, or other clinical symptoms. The most promising are plasma biomarkers, which detect abnormal proteins that accumulate in the brains of people with Alzheimer’s disease, Parkinson’s disease, and related conditions. Plasma p-tau217, for example, shows exceptional sensitivity and specificity for identifying Alzheimer’s pathology, meaning it catches the disease accurately without generating false alarms. What makes multi-disease testing particularly powerful is that several biomarkers appear across different neurological diseases. Plasma biomarkers can differentiate between Parkinson’s disease dementia, dementia with Lewy bodies, and healthy patients when combined with clinical testing.
This means a single screening panel can assess risk for multiple conditions simultaneously rather than requiring separate evaluations. A 45-year-old with a family history of Alzheimer’s and tremor symptoms doesn’t need three different specialist appointments and three different diagnostic procedures—one blood draw could screen for Alzheimer’s pathology, Parkinson’s pathology, and vascular cognitive impairment all at once. The clinical advantage is measurable. Blood and urine biomarkers offer non-invasive, low-cost, and frequent-monitoring capabilities that are suitable for wide clinical application across diverse populations. Plasma biomarkers demonstrate superior sensitivity and specificity over cerebrospinal fluid (the gold standard in research settings) for detecting Alzheimer’s disease, meaning the blood test is actually more reliable than the invasive spinal tap procedure that has been the reference standard for decades.
From Blood Tests to Early Detection: Replacing Invasive Diagnostic Methods
Historically, definitive brain disease diagnosis required either a positron emission tomography (PET) scan costing $3,000-$5,000 or a lumbar puncture (spinal tap) that carries infection risk and requires specialist coordination. Many people never pursued diagnosis because these barriers were too high. blood-based biomarkers are redefining dementia diagnosis by enabling simple blood tests as the first screening step—the same infrastructure used for routine medical care. This shift addresses a critical limitation in current brain health screening: the majority of people with cognitive impairment or preclinical disease pathology never get screened at all. When Mini-Cog screenings (brief cognitive tests) were implemented through Area Agencies on Aging, they identified cognitive impairment in 39% of 569 screened clients in early 2025.
This substantial identification rate suggests that screening infrastructure exists and can work—but only if the screening tool is accessible enough for people to actually use it. A blood test ordered by a primary care doctor during an annual checkup could reach millions more people than specialist-based diagnostic programs ever will. The limitation is that a positive biomarker doesn’t automatically mean a person will develop dementia symptoms or timeline. Amyloid and tau pathology in the brain can exist for 15-20 years before cognitive decline becomes noticeable. Multi-disease testing identifies biological risk but doesn’t yet predict which people will progress rapidly versus remain stable for decades. This creates an important clinical decision point: identifying preclinical disease opens the possibility of early intervention, but also raises questions about how to counsel people about results that indicate pathology but not imminent disease.
Real-World Implementation: How Multi-Disease Testing Identifies Hidden Cognitive Decline
When multi-disease testing is implemented systematically, it identifies populations that current clinical care misses entirely. The 2025 Mini-Cog screening initiative revealed that roughly 4 in 10 older adults screened had cognitive impairment—but many had never mentioned memory concerns to their doctors, and their doctors had never referred them for evaluation. Multi-disease biomarker testing could identify these people earlier, when the pathological process is less advanced. One practical example is screening in primary care during hypertension or diabetes management visits. A 60-year-old coming in for blood pressure medication refill could have their blood drawn for routine metabolic panel plus a multi-disease neurological biomarker panel.
If the biomarker results show Parkinson’s disease-related pathology, that person could begin neuroprotective treatments or monitoring protocols before motor symptoms appear. If the biomarker pattern shows Alzheimer’s pathology with vascular disease components, lifestyle interventions targeting cardiovascular health could be intensified. The implementation advantage is timing and accessibility. Rather than requiring a person to seek a neurologist referral, suffer through the uncertainty of a specialist wait list, and undergo expensive imaging, the screening happens where people already go for care. Automated brain health risk scores are being developed using electronic health records to enable population-wide screening—algorithms that can flag high-risk individuals without requiring manual specialist review. This scales screening from thousands of people in research settings to potentially millions in routine clinical practice.
The Cost and Accessibility Advantage of Screening Multiple Brain Diseases Simultaneously
Screening multiple neurological diseases in one panel dramatically improves cost-effectiveness compared to separate diagnostic pathways. A person with cognitive concerns currently might undergo PET imaging ($3,500), neuropsychological testing ($1,500), and specialist evaluation ($500), totaling $5,500 before any diagnosis is reached. A multi-disease biomarker panel costs a fraction of this—typically $200-$500—and provides information about risk for multiple conditions rather than one. The accessibility advantage extends to underserved populations and rural communities that lack easy access to neurology specialists. A blood test can be ordered by any primary care provider, collected at any lab, and analyzed centrally.
This democratizes brain health screening rather than concentrating it in urban medical centers with specialty neurology. For someone living two hours from the nearest neurologist, accessing multi-disease screening through their family doctor represents genuine healthcare access improvement. The tradeoff is that population-level screening identifies many people with preclinical pathology who would never have sought diagnosis. This creates what researchers call the “labeling” problem: telling a 55-year-old with no symptoms that their blood shows Alzheimer’s pathology can generate anxiety and may influence insurance or employment outcomes. Multi-disease testing’s accessibility advantage depends on having clear frameworks for counseling patients about preclinical results and evidence-based interventions available for people identified through screening.
Limitations and Challenges in Multi-Disease Testing for Brain Health
The most significant limitation is that biomarker positivity doesn’t equal disease inevitability. Research shows that roughly 30% of cognitively normal older adults have Alzheimer’s pathology in their brains at autopsy—they died of other causes without ever developing dementia symptoms. Multi-disease testing could therefore identify many people with biological pathology who will never develop clinical symptoms, and distinguishing between these groups remains an unsolved problem. Another challenge is standardization and interpretation. Different laboratories use different assay platforms for measuring plasma biomarkers, and cutoff values for what constitutes “positive” results still vary.
Multi-disease testing panels compound this complexity because they simultaneously assess risk for Alzheimer’s disease, Parkinson’s disease, vascular dementia, and other conditions—each with different biomarker signatures and different clinical implications. A person might have positive Alzheimer’s biomarkers but negative Parkinson’s biomarkers, requiring nuanced clinical interpretation about their specific neurological risk profile. The warning for current implementation is that interventions for preclinical disease are still limited. While anti-amyloid monoclonal antibodies show modest benefits for people with cognitive impairment plus amyloid pathology, the evidence for treating asymptomatic individuals with preclinical biomarker positivity remains preliminary. Multi-disease testing can identify risk earlier, but the promise of earlier intervention depends on research validating that treating preclinical pathology actually prevents or delays symptom onset—a question still being studied in ongoing trials.
Emerging Technologies Beyond Blood Tests: Tear and Olfactory Biomarkers
Multi-disease screening is expanding beyond blood tests to other accessible body fluids and simple functional assessments. Tear biomarkers have demonstrated diagnostic implications across Alzheimer’s, Parkinson’s, and Multiple Sclerosis, offering another non-invasive sampling method that could complement blood biomarkers. A tear sample collected during a routine eye exam could provide neurological disease information without the need for blood draws or lab infrastructure.
A particularly innovative approach is AROMHA, a remote olfactory assessment test for screening cognitive impairment that works reliably in both observed and unobserved remote self-administration and across English and Spanish speakers. Olfactory dysfunction is an early sign of Parkinson’s disease and cognitive decline, yet olfaction is rarely assessed in routine medical care. A test that can be administered remotely and automatically scored removes barriers to widespread screening and reaches people who might not access laboratory-based testing.
The Future of Brain Health Screening: Population-Wide Risk Assessment
The CDC’s Healthy Brain Initiative, marking its 20th anniversary in 2025, has positioned Alzheimer’s disease and related dementias as public health priorities requiring population-level screening and prevention strategies. This institutional commitment suggests that multi-disease testing will expand from specialty research settings into routine public health infrastructure over the coming years.
The convergence of multiple screening technologies—blood biomarkers, tear biomarkers, olfactory assessments, and automated risk algorithms from electronic health records—points toward a future where brain health screening is integrated into primary care as systematically as cancer screening or cardiovascular risk assessment. The statistic that 1 in 3 people will develop a neurological disorder during their lifetime underscores why this shift matters: mass screening infrastructure is required to identify the billions of people at risk before symptoms compromise their quality of life and independence.
Conclusion
Multi-disease testing has the potential to identify neurological disease pathology decades earlier than current clinical practice, shifting brain health from reactive management of symptoms to proactive screening and early intervention. By measuring shared biomarkers across Alzheimer’s disease, Parkinson’s disease, and related conditions through a single blood test, healthcare systems could screen vastly more people, reach underserved populations, and identify preclinical disease when interventions are most likely to be effective.
The pathway forward requires continued research validating that early intervention in biomarker-positive asymptomatic individuals actually prevents or delays symptom onset, standardized interpretation frameworks across different laboratory platforms, and patient communication strategies for discussing preclinical results. The technology for multi-disease screening already exists; the question now is how rapidly healthcare systems will integrate these screening approaches into routine practice, and whether populations will have equitable access to brain health screening regardless of geography or economic circumstances.
You Might Also Like
- What Hidden Brain Changes May Lead to Dementia?
- Why 3D Brain Models Are Important for Alzheimer’s Drug Testing
- Could Hidden Brain Cells Drive Dementia Progression?
For more, see NIH MedlinePlus — dementia.
